Table 3.
Validation of the Clinseq-G model in the GSE6891 cohort, multivariable survival analysis conducted by Cox regression models
| Factor | Overall survival |
Event-free survival |
||
|---|---|---|---|---|
| HR (95% CI) | P * | HR (95% CI) | P * | |
| Prognostic score† | 2.02 (1.33 to 3.08) | .001 | 2.10 (1.42 to 3.12) | <.001 |
| Age | 1.01 (1.00 to 1.02) | .06 | 1.00 (0.99 to 1.01) | .39 |
| Male sex | 0.94 (0.74 to 1.20) | .64 | 1.04 (0.83 to 1.31) | .72 |
| Cytogenetic risk (intermediate) | 2.49 (1.64 to 3.79) | <.001 | 2.15 (1.46 to 3.16) | <.001 |
| Cytogenetic risk (poor) | 3.73 (2.36 to 5.88) | <.001 | 3.40 (2.23 to 5.17) | <.001 |
| NPM1 (positive) | 0.53 (0.38 to 0.73) | <.001 | 0.52 (0.38 to 0.71) | <.001 |
| FLT3-ITD (positive) | 1.63 (1.23 to 2.17) | .001 | 1.58 (1.19 to 2.10) | .001 |
| CEBPA (double mutated) | 0.36 (0.18 to 0.72) | .004 | 0.42 (0.23 to 0.77) | .005 |
| Stem cell transplantation | 1.69 (1.28 to 2.22) | <.001 | 1.38 (1.07 to 1.79) | .01 |
| White blood cell count | 1.0019 (0.9998 to 1.0040) | .07 | 1.0024 (1.0005 to 1.0044) | .01 |
| Percentage of bone marrow blast | 0.9947 (0.9896 to 0.9999) | .048 | 0.9926 (0.9877 to 0.9975) | .003 |
*
Two-sided likelihood ratio test. CI = confidence interval; HR = hazard ratio.
†
Prognostic score was predicted by the Clinseq-G model.